缩泉益肾方通过抑制YTHDF1-Rubicon轴促进自噬改善糖尿病肾病肾脏细胞衰老
本研究结合db/db小鼠与高糖诱导的HK-2细胞模型,探究缩泉益肾方改善糖尿病肾病肾脏细胞衰老的机制。研究发现该方通过靶向降低YTHDF1表达,抑制Rubicon mRNA稳定性与蛋白翻译,从而促进自噬、减轻衰老与肾损伤。
要点
- 缩泉益肾方可减轻db/db小鼠及高糖HK-2细胞的肾脏衰老与损伤。
- 其抗衰老作用依赖自噬增强,自噬抑制剂Bafilomycin A1可消除该效应。
- 机制为靶向降低YTHDF1,抑制Rubicon mRNA稳定性与翻译,促进自噬。
核心结论
- 缩泉益肾方通过靶向降低YTHDF1表达,抑制Rubicon mRNA稳定性与蛋白翻译,促进自噬,从而改善糖尿病肾病肾脏细胞衰老。
研究设计与样本
- 采用体内db/db小鼠与体外高糖诱导HK-2细胞的糖尿病肾病模型,干预包括缩泉益肾方水提物与含药血清。
- 通过UHPLC-QTOF-MS筛选59种化学成分,并结合网络药理学预测自噬与细胞衰老相关通路。
主要发现
- db/db小鼠肾脏及高糖环境HK-2细胞出现衰老与损伤,缩泉益肾方可改善这些异常变化。
- 缩泉益肾方增强肾组织与细胞自噬,而自噬抑制剂Bafilomycin A1共处理可消除其抗衰老效应。
- 糖尿病肾病进展伴随Rubicon mRNA与蛋白水平升高及m6A修饰增加,缩泉益肾方下调Rubicon mRNA与蛋白但不影响m6A修饰水平。
- 缩泉益肾方靶向降低YTHDF1表达;HK-2细胞过表达YTHDF1可增加Rubicon mRNA稳定性与蛋白表达,并逆转缩泉益肾方诱导的自噬增强与衰老改善。
临床怎么用
- 缩泉益肾方改善糖尿病肾病肾脏衰老的作用与自噬增强相关,临床关注其与自噬调节相关的疗效机制。
- YTHDF1-Rubicon轴可作为糖尿病肾病治疗与缩泉益肾方应用机制的潜在靶点参考。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
SuoquanYishen formula (SQYSF), a traditional Chinese herbal prescription for treating diabetic kidney disease (DKD), has demonstrated clinical efficacy in lowering blood glucose and alleviating renal damage. Emerging evidence implicates cellular senescence as a critical contributor to DKD progression. This study aimed to elucidate the mechanism by which SQYSF improves renal cellular senescence using both in vivo (db/db mice) and in vitro (high glucose-induced HK-2 cells) DKD models, with interventions involving SQYSF aqueous extract and SQYSF-containing serum. We screened 59 chemical compounds by UHPLC-QTOF-MS and used network pharmacology approach to discover that autophagy and cellular senescence are important pathways for pharmacological treatment of disease. Experimental validation demonstrated that senescence and damage occurred in the kidneys of db/db mice and HK-2 cells under high glucose environment, and SQYSF ameliorated these abnormal changes. Then, we also found that SQYSF enhanced autophagy in renal tissues and cells, whereas co-treatment with the autophagy inhibitor Bafilomycin A1 abolished SQYSF's anti-senescence effects. Notably, DKD progression was associated with elevated Rubicon expression at mRNA and protein levels, accompanied by increased m6A modification. While SQYSF effectively downregulated Rubicon mRNA and protein expression, it did not influence m6A modification levels. Further investigation identified that SQYSF was able to target to reduce YTHDF1 expression level. Overexpression of YTHDF1 in HK-2 cells increased Rubicon mRNA stability and protein expression, while concurrently reversing SQYSF-induced autophagy enhancement and senescence amelioration. These results suggest that SQYSF exerts its role in ameliorating renal cellular senescence in DKD by targeting to reduce the expression level of YTHDF1, which inhibits the level of Rubicon mRNA and protein translation, and thus promotes autophagy. Our results reveal the active components and mechanisms of SQYSF for the treatment of DKD, which may provide useful information to guide the clinical application of SQYSF as well as the therapeutic pathway for DKD.
引用
- Yan Z, Zhang L, Ma T, et al. SuoquanYishen formula improves renal cellular senescence by inhibiting YTHDF1-Rubicon axis to promote autophagy in diabetic kidney disease. Front Pharmacol. 2025. PMID: 40371338. doi:10.3389/fphar.2025.1543277
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。